| B58 | Plasma IP-10 concentrations show no correlation with HIV infection in children attending hospitals in Blantyre and Mulanje, Malawi | E-poster | Diagnosis of HIV disease in paediatric and adolescent populations |
| B60 | Assessing parental choice of lopinavir/ritonavir granules intake to improve child adherence at Baylor-Mwanza, Tanzania | E-poster | Drug formulations for infants and children |
| B60 | Acceleration of pediatric ART regimen optimization during COVID-19 epidemic using self-learning for health care workers in Malawi | E-poster | Drug formulations for infants and children |
| B60 | Proof of principle oral dissolvable strip formulation for pediatric ARV prophylaxis | E-poster | Drug formulations for infants and children |
| B60 | Caregivers perception on paedriatic lopinavir/ritonavir formulations for HIV-infected children at Baylor Clinic, Mwanza, Tanzania | E-poster | Drug formulations for infants and children |
| B60 | Low viral suppression in children < 3 years old on two protease inhibitor formulations in Kenya, 2015-2019 | E-poster | Drug formulations for infants and children |
| B37 | NNRTI MK-8507 does not alter the pharmacokinetics of the combined oral contraceptive levonorgestrel/ethinyl estradiol | E-poster | Drug interactions |
| B37 | Persistence of drug-drug interaction problems with contemporary antiretroviral therapy. The case of ergotism | E-poster | Drug interactions |
| B37 | No pharmacokinetic interaction between novel NNRTI MK-8507 and Islatravir | E-poster | Drug interactions |
| B8 | Plasma separation cards are suitable for HIV-1 genotypic drug resistance testing | On-demand oral abstract session | Drug resistance testing |